Figure 4 | Gene Therapy

Figure 4

From: Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure

Figure 4

Massons Trichrome staining for collagen content. Left ventricular fibrosis declined in the pCMVe-SDF1 group (a) and pCMV-SDF1 group (b) compared to the saline group (c) (n=7 in all groups). SDF-1 gene therapy reduced infarct size 8 weeks after treatment in chronic heart failure. (d) Decrease in fibrotic scar following SDF-1 treatment. This correlates to a–c. The left ventricular fibrotic area was smaller in the pCMVe-SDF1 (16.92±2.82%) and pCMV-SDF1 groups (17.81±2.59%), compared to the saline group (23.82±4.47%) (n=7 in all groups), #P=0.08, demonstrating a trend towards reduced scar tissue following plasmid injections.

Back to article page